Automate Your Wheel Strategy on MRNA
With Tiblio's Option Bot, you can configure your own wheel strategy including MRNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRNA
- Rev/Share 8.1839
- Book/Share 26.0777
- PB 1.3145
- Debt/Equity 0.074
- CurrentRatio 4.2182
- ROIC -0.3311
- MktCap 13257515760.0
- FreeCF/Share -10.4249
- PFCF -3.2946
- PE -3.9416
- Debt/Assets 0.0586
- DivYield 0
- ROE -0.301
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MRNA | Citigroup | -- | Neutral | -- | $40 | March 13, 2025 |
| Downgrade | MRNA | Barclays | Overweight | Equal Weight | $111 | $45 | Feb. 18, 2025 |
| Downgrade | MRNA | Goldman | Buy | Neutral | $99 | $51 | Jan. 29, 2025 |
| Downgrade | MRNA | Argus | Buy | Hold | -- | -- | Dec. 18, 2024 |
| Resumed | MRNA | BofA Securities | -- | Underperform | -- | $41 | Dec. 10, 2024 |
| Initiation | MRNA | Bernstein | -- | Market Perform | -- | $55 | Oct. 17, 2024 |
| Downgrade | MRNA | Jefferies | Buy | Hold | $120 | $65 | Sept. 13, 2024 |
| Downgrade | MRNA | JP Morgan | Neutral | Underweight | $88 | $70 | Sept. 13, 2024 |
| Downgrade | MRNA | Oppenheimer | Outperform | Perform | -- | -- | Sept. 13, 2024 |
| Upgrade | MRNA | HSBC Securities | Reduce | Hold | -- | $82 | Aug. 28, 2024 |
News
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.
Read More
This Former Meme Stock, Down 93%, is a High-Upside Buy Right Now
Published: July 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago.
Read More
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.
Read More
Moderna Stock Gains on Encouraging Flu Vaccine Data
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.
Read More
Top Stock Movers Now: Hewlett Packard Enterprise, Moderna, Tesla, and More
Published: June 30, 2025 by: Investopedia
Sentiment: Positive
U.S. equities gained at midday, with the S&P 500 and Nasdaq adding to their all-time highs, on optimism about more U.S. trade deals. The Dow Jones Industrial Average was up as well.
Read More
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine
Published: June 30, 2025 by: WSJ
Sentiment: Positive
The biotechnology company's messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Read More
Moderna (MRNA) Advances While Market Declines: Some Information for Investors
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the most recent trading session, Moderna (MRNA) closed at $25.90, indicating a +1.97% shift from the previous trading day.
Read More
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Published: June 10, 2025 by: Reuters
Sentiment: Neutral
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday.
Read More
Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference Transcript
Published: June 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Jonathan Yee - Jefferies LLC, Research Division Michael Jonathan Yee Hi, everyone. Thank you.
Read More
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.
Read More
Moderna, favored by the first Trump administration for its Covid-19 vaccine, is now in trouble as Trump 2.0 shifts its position on vaccine-making
Published: June 02, 2025 by: WSJ
Sentiment: Negative
The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.
Read More
Moderna: Vaccine Approval (Finally!) Provides A Reason To Be Cheerful
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
Moderna's new COVID vaccine approval targets a broader high-risk population, but the market remains skeptical due to limited revenue prospects and ongoing losses. Management is pivoting to cost-cutting, pipeline focus, and realistic revenue guidance after overreaching post-pandemic and burning through cash on speculative projects. Despite leadership changes at HHS and FDA and loss of government funding, Moderna could outperform 2025 guidance if vaccination rates and combo shots gain traction.
Read More
Top Stock Movers Now: Ford, Cleveland-Cliffs, Moderna, and More
Published: June 02, 2025 by: Investopedia
Sentiment: Negative
U.S. equities were mixed at midday after China hit back at the U.S. and accused Washington of violating a trade deal the two countries reached last month. President Donald Trump said on Friday that China had "totally violated" the truce they struck in Geneva.
Read More
Moderna moves higher on FDA approval of new COVID-19 vaccine
Published: June 02, 2025 by: Proactive Investors
Sentiment: Positive
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares edged higher after the US Food and Drug Administration (FDA) approved its newest COVID-19 vaccine mNEXSPIKE (mRNA-1283). The vaccine was approved for use in adults aged 65 and older and individuals aged 12 to 64 who have at least one underlying health risk factor as defined by the Centers for Disease Control and Prevention (CDC), Moderna said on Monday.
Read More
Moderna Stock Is Rising. A New Covid Vaccine Is Coming for Some People.
Published: June 02, 2025 by: Barrons
Sentiment: Positive
Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.
Read More
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
Published: June 02, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.'s MRNA mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).
Read More
Moderna, Inc. (MRNA) Bernstein 41st Annual Strategic Decisions Conference Call Transcript
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Bernstein 41st Annual Strategic Decisions Conference Call May 29, 2025 10:00 AM ET Company Participants Stephane Bancel - CEO & Director Conference Call Participants Courtney Breen - Bernstein Courtney Breen So I am thrilled to be here today with Stephane Bancel from Moderna. My name is Courtney Breen.
Read More
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.
Read More
Cautious? Risky? Our Volatility Scorecard Can Help
Published: May 27, 2025 by: Schaeffers Research
Sentiment: Neutral
Our volatility scorecard has a pretty good feel for the market right now.
Read More
Will Moderna's Rally Continue?
Published: May 26, 2025 by: Forbes
Sentiment: Positive
Moderna (NASDAQ: MRNA) has caught the market off guard with a significant recovery in recent days – reaching current levels of approximately $27 after hitting a five-year low of $23.15 last week – following the FDA's decision to continue advising annual COVID-19 vaccinations for high-risk populations. However, this abrupt rally appears to be a singular occurrence – competitors such as Pfizer (NYSE: PFE), Sarepta Therapeutics (NASDAQ: SRPT), and CureVac (NASDAQ:CVAC) did not replicate Moderna's increase – implying the rise was primarily fueled by the FDA guidance rather than a wider sector uptrend.
Read More
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
Read More
Moderna Stock Looks Ripe for a Short Squeeze
Published: May 22, 2025 by: MarketBeat
Sentiment: Neutral
Moderna Inc. NASDAQ: MRNA is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 months.
Read More
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
Read More
Moderna withdraws application for COVID-flu combination vaccine
Published: May 21, 2025 by: Reuters
Sentiment: Negative
Moderna said on Wednesday it had withdrawn the pending application for its flu and COVID combination vaccine candidate for adults aged 50 years and older.
Read More
Moderna shares surge as new FDA vaccine framework eases investor concerns
Published: May 20, 2025 by: Proactive Investors
Sentiment: Positive
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares jumped more than 6.5% on Tuesday after the US Food and Drug Administration unveiled a new framework for COVID-19 vaccine approvals that analysts said largely maintains the status quo for the company's core market. The FDA's updated guidance does not change how COVID-19 vaccines are authorized for individuals aged 65 and older or those aged six months to 64 years who are at high risk.
Read More
Top Stock Movers Now: Viking, Moderna, Uber Technologies, and More
Published: May 20, 2025 by: Investopedia
Sentiment: Negative
U.S. equities were lower at midday, dragged by tech and travel stocks. The Dow Jones Industrial Average, S&P 500, and Nasdaq were all lower.
Read More
Moderna: After A Crash From $500 To $25, I'm Buying This "Call Option" On Pandemics And Cancer
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Moderna's share price has collapsed from $500 to $25, but I believe the selloff is overdone, and the stock is deeply oversold. Short squeeze potential, a robust pipeline, and long-term mRNA/AI opportunities could drive a significant rebound, despite near-term losses and vaccine skepticism. Moderna's strong balance sheet, insider buying, and promising oncology candidates add to my conviction for a small, speculative position.
Read More
Cautious? Risky? Our Volatility Scorecard Can Help
Published: May 13, 2025 by: Schaeffers Research
Sentiment: Neutral
Subscribers to Chart of the Week received this commentary on Sunday, May 11.
Read More
Why Moderna Merged Its Tech and HR Departments
Published: May 12, 2025 by: WSJ
Sentiment: Neutral
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech.
Read More
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
Read More
About Moderna, Inc. (MRNA)
- IPO Date 2018-12-07
- Website https://www.modernatx.com
- Industry Biotechnology
- CEO Stephane Bancel
- Employees 5800